Prescription drugs, products liability, and preemption of tort litigation

JAMA

Volumn 300, Issue 16, 2008, Pages 1939-1941

  DeAngelis, Catherine D ^a   Fontanarosa, Phil B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; PROMETHAZINE;

CATHETER COMPLICATION; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GANGRENE; HUMAN; LAW SUIT; LEGAL LIABILITY; MIGRAINE; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VASCULAR DISEASE;

EID: 54349116761     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.513     Document Type: Editorial

References (18)

1. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2006.
2. Food and Drug Administration. Science Board. Science and Mission at Risk: Report of the Subcommittee on Science and Technology. Washington, DC: FDA; 2007.
3. FDA Amendments Act (FDAAA) of 2007, Pub L No. 110-85, 121 Stat 823.
4. Psaty BM, Korn D. Congress responds to the IOM Drug Safety Report - in full. JAMA. 2007;298(18):2185-2187.
5. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA. 2004;292(21):2647-2650.
6. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887-1896.
7. Gostin LO. The deregulatory effects of preempting tort litigation: FDA regulation of medical devices. JAMA. 2008;299(19):2313-2316.
8. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007; 297(3):308-311.
9. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299(15):1813-1817.
10. Ross JS, Hill KP, Egilmn DS, Krumholz HM. Guest authroship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299(15):1800-1812.
11. Levine v Wyeth, 2006 VT 107 (Vt 2006), cert granted, 128 SCt 1118 (2008).
12. Riegel v Medtronic Inc, 128 SCt 999 (2008).
13. Medical Device Amendments (MDA), 21 USC §360k(a) (1976).
14. Federal Food, Drug, and Cosmetic Act, 21 USC §301 et seq.
15. Feder BJ. Medical device ruling redraws lines on lawsuits. New York Times. February 22, 2008. http://www.nytimes.com/2008/02/22/business/22device. html?scp=1&sq= Medical%20device%20ruling%20redraws%20lines%20on%20lawsuits&st=cse.
16. Kessler DA, Vladeck DC. A critical examination of the FDA's efforts to preempt failure-to-warn claims. Georgetown Law J. 2008;96:461-495.
17. Wright v Aventis Pasteur, PA Super 203 (2006); 905 A2d 544; Pa Super LEXIS 1728 (Pa Super. Ct 2006); Appeal denied, 591 Pa 674; 916 A2d 1103 (Pa 2007); dismissal entered, 2008 Phila Ct Com Pl LEXIS 221 (August 27, 2008).
18. FDA embarks on Major hiring initiative for its public health mission [news release]. Rockville, MD: Food and Drug Administration; 2008. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01829.html. Accessed September 29, 2008.